Tazobactum%25252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview A combination of an extended-spectrum penicillin (piperacillin) and a beta-lactamase inhibitor (tazobactam). It provides coverage against Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic organisms. Usually formulated in an 8:1 fixed ratio. ## Primary Indications * Hospital-acquired and ventilator-associated pneumonia. * Complicated intra-abdominal infections. * Complicated skin and skin structure infections. * Febrile neutropenia (often combined with an aminoglycoside). * Sepsis/bacteremia. ## Adult Dosing * **Standard:** 3.375 g (3 g piperacillin / 0.375 g tazobactam) IV every 6 hours. * **Severe Infections:** 4.5 g (4 g piperacillin / 0.5 g tazobactam) IV every 6 hours. * **Administration:** Infuse over 4 hours for critically ill patients to optimize pharmacodynamics (time above MIC). ## Pediatric Dosing * **Neonates (0–9 days):** 80 mg/kg (piperacillin) every 12 hours. * **Neonates (10–44 days):** 80 mg/kg (piperacillin) every 8 hours. * **Children ≥ 9 months to 12 years:** 80-100 mg/kg (piperacillin) every 8 hours (max 4g piperacillin per dose). * *Note: Always consult institutional guidelines for neonatal/pediatric dosing per specific weight/post-menstrual age.* ## Dose Adjustments * **Renal Impairment:** Requires reduction based on Creatinine Clearance (CrCl). * CrCl 20–40 mL/min: 2.25 g every 6 hours. * CrCl < 20 mL/min: 2.25 g every 8 hours. * **Hemodialysis:** 2.25 g every 8 hours, with an additional 0.75 g dose after each dialysis session. * **Hepatic Impairment:** No standard dosage adjustment needed. ## Contraindications * Known hypersensitivity to piperacillin, tazobactam, or any beta-lactam (including penicillins and cephalosporins). * History of anaphylaxis to any beta-lactam. ## Adverse Effects * **Common:** Diarrhea (including *C. difficile* risk), nausea, constipation, headache. * **Serious:** Anaphylaxis, hypersensitivity reactions, seizures (rare, mostly in renal impairment), leukopenia/neutropenia (with prolonged use), hepatotoxicity. ## Key Drug Interactions * **Aminoglycosides:** Piperacillin can inactivate aminoglycosides *in vitro* if mixed in the same IV line. Administer at least 1 hour apart. * **Probenecid:** Increases serum concentrations of piperacillin/tazobactam by decreasing renal tubular secretion. * **Methotrexate:** Penicillins may decrease renal clearance, increasing risk of methotrexate toxicity. * **Warfarin:** Possibility of prolonged PT/INR due to effects on gut flora or potential platelet inhibition. ## Monitoring * **Renal:** Monitor serum creatinine and urine output. * **Hematologic:** Periodic CBC with differential (especially if therapy exceeds 7–10 days due to risk of neutropenia). * **Clinical:** Monitor for signs of *C. difficile* infection (unexplained diarrhea) and clinical improvement of infection markers (WBC, fever). * **Electrolytes:** Sodium intake (contains 2.79 mEq of sodium per 1g of piperacillin). ## Clinical Pearls * Not indicated for the treatment of meningitis (poor CNS penetration). * Often used as empirical broad-spectrum therapy in critically ill patients. * De-escalate to narrower therapy once culture and sensitivity results are available to promote antimicrobial stewardship. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines vary by institution and patient-specific factors. Always verify current prescribing information, institutional protocols, and pharmacokinetic data before administering medications.*